Regulatory

June 30, 2023

First ten HER2-low patients dosed in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, June 30, 2023. Affibody AB (“Affibody”) today announced that the first ten patients have been dosed in a Phase 2 clinical basket study of the PET imaging...

Read more

News

May 23, 2023

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 23, 2023 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Read more

News

May 16, 2023

First Izokibep Publication

Solna, Sweden, May 16, 2023. The first publication outlining the pre-clinical development and first-in-human study of izokibep is now available online. The article, Izokibep: Preclinical development and first-in-human study...

Read more

Regulatory

April 11, 2023

Positive Long-term Results with Izokibep in Psoriatic Arthritis

• Affibody’s partner ACELYRIN, INC today announced 46 weeks Phase 2 data where izokibep demonstrated high levels of response across psoriatic arthritis disease manifestations.• Long-term data build on statistically...

Read more

Regulatory

March 30, 2023

Affibody appoints Peter Zerhouni as CBO

· Peter Zerhouni joins as Chief Business Officer on April 3, 2023. Solna, Sweden, March 30, 2023 – Affibody AB (“Affibody”) today announced the appointment of Peter Zerhouni as CBO. He...

Read more

Regulatory

March 18, 2023

Izokibep Phase 2b/3 Hidradenitis Suppurativa Data Presented at the 2023 American Academy of Dermatology Annual Meeting

• At 12 weeks, 57% of patients achieved HiSCR75, 38% achieved HiSCR90 and 33% achieved HiSCR100. • Safety results were consistent with previous trials of izokibep, with no increased...

Read more

Regulatory

March 7, 2023

Affibody and Chiesi Group collaborate to develop and commercialize innovative treatments for respiratory diseases

Affibody and Chiesi Group will collaborate closely to develop novel Affibody® molecules as innovative treatments for respiratory diseases.  This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with...

Read more

Regulatory

January 5, 2023

Positive Top-line Clinical Data for Izokibep in Hidradenitis Suppurativa

Solna, Sweden, January 5, 2023. Affibody’s partner ACELYRIN, Inc. today announced top-line 12-week open label data from a Phase 2b/3 trial of izokibep in patients with moderate-to-severe Hidradenitis Suppurativa...

Read more

Regulatory

January 4, 2023

First HER2-low patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, January 4, 2023. Affibody AB (“Affibody”) today announced that the first patients have been dosed in a Phase 2 clinical basket study of the PET imaging agent...

Read more